International Liver Congress | Conference

Dr. Bruix Discusses the Application of Regorafenib in HCC

April 28th 2017

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the application of regorafenib (Stivarga) in hepatocellular carcinoma as opposed to other tumor types.

Dr. Pinato on Study of Sorafenib in Pretreated Patients With HCC

April 28th 2017

David James Pinato, MD, MRCP, PhD, faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of sorafenib (Nexavar) in pretreated patients with hepatocellular carcinoma (HCC).

Dr. Satapathy on Recurrence in Orthotopic Liver Transplant Recipients With HCC

April 25th 2017

Sanjaya K. Satapathy, MD, associate professor, Transplant Hepatology Division of Surgery, Methodist University Hospital Transplant Institute, University of Tennessee Health Sciences Center, discusses preventing recurrence in orthotopic liver transplant recipients with hepatocellular carcinoma.

Dr. Sangro Discusses Safety Profile of Nivolumab in HCC

April 25th 2017

Bruno Sangro, MD, PhD, head of Hepatology Unit, Internal Medicine Department, Clinica Universidad de Navarra, discusses the safety profile of nivolumab (Opdivo) in advanced hepatocellular carcinoma (HCC).

Regorafenib Success Revives Hope in HCC

April 23rd 2017

Jordi Bruix, MD, discusses the success of regorafenib in hepatocellular carcinoma and its impact on the field going forward.

Mipsagargin Demonstrates Clinical Benefit in Patients With Advanced HCC

April 22nd 2017

The first-in-class prodrug, mipsagargin (G-202), showed promising antitumor activity and enabled patients with advanced sorafenib-refractory hepatocellular carcinoma to achieve disease stabilization.

SIRT Better-Tolerated Than Sorafenib in Advanced HCC

April 22nd 2017

Liver-targeting treatment with selective internal radiation therapy more effectively controlled liver tumor progression and was better tolerated in patients with hepatocellular carcinoma, but the therapy did not improve rates of overall or progression-free survival over sorafenib.

Dr. Abi-Jaoudeh on Combination of Tirapazamine and Transarterial Embolization in HCC

April 22nd 2017

Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the combination of tirapazamine (SR-4233) and transarterial embolization in hepatocellular carcinoma (HCC).

Dr. Bruix Discusses the Success of Regorafenib in HCC

April 22nd 2017

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the recent success of regorafenib (Stivarga) in hepatocellular carcinoma (HCC) and its impact on the field.

Potential Biomarker for Survival Emerges in Hepatocellular Carcinoma

April 22nd 2017

Log10 alpha fetoprotein level in the blood directly corresponded to the months of posttreatment survival in patients with hepatocellular carcinoma, independent of the type of treatment, regional differences, and disease etiology.

Nivolumab Provides Durable Responses in Sorafenib-Experienced HCC Patients

April 21st 2017

Sorafenib-experienced patients with advanced hepatocellular carcinoma had long-term responses to nivolumab of more than 1 year, according to findings from the CheckMate-040 trial.

DAA Therapy for Hepatitis C May Increase HCC Recurrence Risk

April 21st 2017

Spanish researchers raised a red flag regarding observations of unexpected higher rates of hepatocellular carcinoma recurrence following treatment with direct-acting antivirals for hepatitis C virus infection.

Dr. Pinato on Study of Immune-Tolerogenic Pathways in Primary and Metastatic HCC

April 21st 2017

David James Pinato, MD, MRCP, PhD, Faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of intratumor heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma.

Dr. Jun on Results of Study in Cryptogenic Hepatocellular Carcinoma

April 21st 2017

Tomi Jun, MD, Stanford University School of Medicine, discusses the results of a study of cirrhosis and long-term survival in patients with cryptogenic hepatocellular carcinoma.

Combinations in HCC Gaining Traction

April 21st 2017

Nadine Abi-Jaoudeh, MD, discusses a study of tirapazamine and transarterial embolization and the promise of combinations in hepatocellular carcinoma.

MicroRNA-34a as a Therapeutic Target in HCC

April 21st 2017

MicroRNA-34a, one of the most documented tumor suppressor microRNAs, is being evaluated as a potential therapeutic target in hepatocellular carcinoma.

Independent Prognostic Markers of HCC Recurrence Identified

April 21st 2017

Higher levels of hepatocytes positive for pERK immunostaining and greater microvascular invasion have emerged as independent prognostic factors of recurrence in patients following sorafenib (Nexavar) treatment for hepatocellular carcinoma.

Dr. Abi-Jaoudeh Discusses Potential of Immunotherapy in Advanced HCC

April 20th 2017

Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the potential for immunotherapy in advanced hepatocellular carcinoma.

MicroRNA-34a in Hepatocellular Carcinoma

April 20th 2017

Amira Abdelhamid, assistant lecturer, German University in Cairo, discusses microRNA-34a and natural killer (NK) cells in hepatocellular carcinoma (HCC).

HCC Risk Comparable in Hepatitis C Patients Treated With DAA or Interferon

April 20th 2017

A meta-analysis found that patients were at no elevated risk of developing hepatocellular carcinoma after achieving sustained virologic response following treatment with direct-acting antiviral therapy for hepatitis C compared to interferon therapy.